Identification and characterization of plant-derived alkaloids, corydine and corydaline, as novel mu opioid receptor agonists.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 08 2020
14 08 2020
Historique:
received:
10
06
2020
accepted:
27
07
2020
entrez:
16
8
2020
pubmed:
17
8
2020
medline:
10
2
2021
Statut:
epublish
Résumé
Pain remains a key therapeutic area with intensive efforts directed toward finding effective and safer analgesics in light of the ongoing opioid crisis. Amongst the neurotransmitter systems involved in pain perception and modulation, the mu-opioid receptor (MOR), a G protein-coupled receptor, represents one of the most important targets for achieving effective pain relief. Most clinically used opioid analgesics are agonists to the MOR, but they can also cause severe side effects. Medicinal plants represent important sources of new drug candidates, with morphine and its semisynthetic analogues as well-known examples as analgesic drugs. In this study, combining in silico (pharmacophore-based virtual screening and docking) and pharmacological (in vitro binding and functional assays, and behavioral tests) approaches, we report on the discovery of two naturally occurring plant alkaloids, corydine and corydaline, as new MOR agonists that produce antinociceptive effects in mice after subcutaneous administration via a MOR-dependent mechanism. Furthermore, corydine and corydaline were identified as G protein-biased agonists to the MOR without inducing β-arrestin2 recruitment upon receptor activation. Thus, these new scaffolds represent valuable starting points for future chemical optimization towards the development of novel opioid analgesics, which may exhibit improved therapeutic profiles.
Identifiants
pubmed: 32796875
doi: 10.1038/s41598-020-70493-1
pii: 10.1038/s41598-020-70493-1
pmc: PMC7427800
doi:
Substances chimiques
Alkaloids
0
Analgesics
0
Aporphines
0
Berberine Alkaloids
0
Receptors, Opioid, mu
0
corydaline
08N392L8VX
corydine
476-69-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13804Subventions
Organisme : Austrian Science Fund FWF
ID : I 2463
Pays : Austria
Références
Devereaux, A. L., Mercer, S. L. & Cunningham, C. W. DARK classics in chemical neuroscience: Morphine. ACS Chem. Neurosci. 9, 2395–2407 (2018).
pubmed: 29757600
Fürst, S. & Hosztafi, S. The chemical and pharmacological importance of morphine analogues. Acta Physiol. Hung. 95, 3–44 (2008).
pubmed: 18389996
Spetea, M., Asim, M. F., Wolber, G. & Schmidhammer, H. The µ opioid receptor and ligands acting at the µ opioid receptor, as therapeutics and potential therapeutics. Curr. Pharm. Des. 19, 7415–7434 (2013).
pubmed: 23448479
Armenian, P. et al. Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review. Neuropharmacology 134, 121–213 (2018).
pubmed: 29042317
Pasternak, G. W. et al. Emerging insights into mu opioid pharmacology. Handb. Exp. Pharmacol. 258, 89–125 (2020).
pubmed: 31598835
Benyamin, R. et al. Opioid complications and side effects. Pain Physician 11, S105–S120 (2008).
pubmed: 18443635
Seth, P., Scholl, L., Rudd, R. A. & Bacon, S. Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. MMWR Morb. Mortal. Wkly. Rep. 67, 349–358 (2018).
pubmed: 29596405
pmcid: 5877356
Volkow, N. D., Jones, E. B., Einstein, E. B. & Wargo, E. M. Prevention and treatment of opioid misuse and addiction: A review. JAMA Psychiatry 76, 208–216 (2019).
pubmed: 30516809
Baumann, M. H. et al. Pharmacological research as a key component in mitigating the opioid overdose crisis. Trends Pharmacol. Sci. 39, 995–998 (2018).
pubmed: 30454770
Skolnick, P. The opioid epidemic: Crisis and solutions. Annu. Rev. Pharmacol. Toxicol. 58, 143–159 (2018).
pubmed: 28968188
Ehrlich, A. T., Kieffer, B. L. & Darcq, E. Current strategies toward safer mu opioid receptor drugs for pain management. Expert Opin. Ther. Targets 23, 315–326 (2019).
pubmed: 30802415
pmcid: 6497449
Turnaturi, R. et al. Progress in the development of more effective and safer analgesics for pain management. Eur. J. Med. Chem. 183, 111701 (2019).
pubmed: 31550662
Stein, C. Opioid receptors. Ann. Rev. Med. 67, 433–451 (2016).
pubmed: 26332001
Corder, G. et al. Endogenous and exogenous opioids in pain. Annu. Rev. Neurosci. 41, 453–473 (2018).
pubmed: 29852083
pmcid: 6428583
Manglik, A. et al. Crystal structure of the mu-opioid receptor bound to a morphinan antagonist. Nature 485, 321–326 (2012).
pubmed: 22437502
pmcid: 3523197
Huang, W. et al. Structural Insights into μ-opioid receptor activation. Nature 524, 315–321 (2015).
pubmed: 26245379
pmcid: 4639397
Koehl, A. et al. Structure of the µ-opioid receptor–Gi protein complex. Nature 558, 547–552 (2018).
pubmed: 29899455
pmcid: 6317904
Grim, T. W., Acevedo-Canabal, A. & Bohn, L. M. Toward directing opioid receptor signaling to refine opioid therapeutics. Biol. Psychiatry 87, 15–21 (2020).
pubmed: 31806082
Valentino, R. J. & Volkow, N. D. Untangling the complexity of opioid receptor function. Neuropsychopharmacology 43, 2514–2520 (2018).
pubmed: 30250308
pmcid: 6224460
Li, J. W. & Vederas, J. C. Drug discovery and natural products: End of an era or an endless frontier?. Science 325, 161–165 (2009).
pubmed: 19589993
Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J. Nat. Prod. 83, 770–803 (2020).
pubmed: 32162523
Kruegel, A. C. et al. Synthetic and receptor signaling explorations of the Mitragyna alkaloids: Mitragynine as an atypical molecular framework for opioid receptor modulators. J. Am. Chem. Soc. 138, 6754–6764 (2016).
pubmed: 27192616
pmcid: 5189718
Kruegel, A. C. & Grundmann, O. The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology 134, 108–120 (2018).
pubmed: 28830758
Kruegel, A. C. et al. 7-Hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects. ACS Cent. Sci. 5, 992–1001 (2019).
pubmed: 31263758
pmcid: 6598159
Cui, X. et al. Ligand interaction, binding site and G protein activation of the mu opioid receptor. Eur. J. Pharmacol. 702, 309–315 (2013).
pubmed: 23415745
pmcid: 3608745
Kaserer, T., Lantero, A., Schmidhammer, H., Spetea, M. & Schuster, D. μ Opioid receptor: Novel antagonists and structural modeling. Sci. Rep. 6, 21548 (2016).
pubmed: 26888328
pmcid: 4757823
Manglik, A. et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature 537, 185–190 (2016).
pubmed: 27533032
pmcid: 5161585
Noha, S. M. et al. Molecular docking, molecular dynamics, and structure-activity relationship explorations of 14-oxygenated N-methylmorphinan-6-ones as potent μ-opioid receptor agonists. ACS Chem. Neurosci. 8, 1327–1337 (2017).
pubmed: 28125215
pmcid: 5481819
Sutcliffe, K. J. et al. Drug binding poses relate structure with efficacy in the μ opioid receptor. J. Mol. Biol. 429, 1840–1851 (2017).
pubmed: 28502792
pmcid: 5472181
Wtorek, K. et al. Endomorphin-2 analogs containing modified tyrosines: Biological and theoretical investigation of the influence on conformation and pharmacological profile. Eur. J. Med. Chem. 179, 527–536 (2019).
pubmed: 31276897
Obeng, S. et al. Structure-activity relationship studies of 6α- and 6β-indolylacetamidonaltrexamine derivatives as bitopic mu opioid receptor modulators and elaboration of the “message-address concept” to comprehend their functional conversion. ACS Chem. Neurosci. 10, 1075–1090 (2019).
pubmed: 30156823
Ellis, C. R. et al. Evaluating kratom alkaloids using PHASE. PLoS ONE 15, e0229646 (2020).
pubmed: 32126112
pmcid: 7053747
Surratt, C. K. et al. Mu opiate receptor Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. J. Biol. Chem. 269, 20548–20553 (1994).
pubmed: 8051154
Mansour, A. et al. Key residues defining the μ-opioid receptor binding pocket: A site-directed mutagenesis study. J. Neurochem. 68, 344–353 (1997).
pubmed: 8978745
Reiter, E. et al. Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu. Rev. Pharmacol. Toxicol. 52, 179–197 (2012).
pubmed: 21942629
Zhou, L. & Bohn, L. M. Functional selectivity of GPCR signaling in animals. Curr. Opin. Chem. Biol. 27, 102–108 (2014).
DeWire, S. M. et al. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J. Pharmacol. Exp. Ther. 344, 708–717 (2013).
pubmed: 23300227
Váradi, A. et al. Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit β-arrestin-2. J. Med. Chem. 59, 8381–8839 (2016).
pubmed: 27556704
pmcid: 5344672
Schmid, C. L. et al. Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell 171, 1165–1175 (2017).
pubmed: 29149605
pmcid: 5731250
Martin, C. et al. Biodegradable amphipathic peptide hydrogels as extended-release system for opioid peptides. J. Med. Chem. 61, 9784–9789 (2018).
pubmed: 30351003
Kenakin, T. & Christopoulos, A. Signaling bias in new drug discovery: Detection, quentification and therapeutic impact. Nat. Rev. Drug Discov. 12, 205–216 (2013).
pubmed: 23411724
Le Bars, D. et al. Animal models of nociception. Pharmacol. Rev. 53, 597–652 (2001).
pubmed: 11734620
Schrödinger Release 2019–4: Maestro, Schrödinger, LLC, New York, NY, 2019.
Keiser, M. J. et al. Relating protein pharmacology by ligand chemistry. Nat. Biotech. 25, 197–206 (2007).
Ma, Z.-Z. et al. Isoquinoline alkaloids isolated from Corydalis yanhusuo and their binding affinities at the dopamine D1 receptor. Molecules 13, 2303–2312 (2008).
pubmed: 18830156
pmcid: 6245449
Wu, L. et al. Identification of alkaloids from Corydalis yanhusuo W.T. Wang as dopamine D1 receptor antagonists by using CRE-luciferase reporter gene assay. Molecules 23, 2585 (2018).
pmcid: 6222624
Ji, H. Y. et al. In vitro metabolism of corydaline in human liver microsomes and hepatocytes using liquid chromatography-ion trap mass spectrometry. J. Sep. Sci. 35, 1102–1109 (2012).
pubmed: 22689485
Rankovic, Z. et al. Biased agonism: An emerging paradigm in GPCR drug discovery. Bioorg. Med. Chem. Lett. 26, 241–250 (2016).
pubmed: 26707396
McClatchey, W. C. et al. Ethnobotany as a pharmacological research tool and recent developments in CNS-active natural products from ethnobotanical sources. Pharmacol. Ther. 123, 239–254 (2009).
pubmed: 19422851
pmcid: 2700180
Prevatt-Smith, K. M. & Prisinzano, T. E. New therapeutic potential for psychoactive natural products. Nat. Prod. Rep. 27, 23–31 (2010).
pubmed: 20024092
Di Marzo, V. Endocannabinoids: Synthesis and degradation. Rev. Physiol. Biochem. Pharmacol. 160, 1–24 (2008).
pubmed: 18481028
Bermudez, M. et al. Strategies for the discovery of biased GPCR ligands. Drug Discov. Today 24, 1031–1037 (2019).
pubmed: 30831262
Scior, T. et al. Recognizing pitfalls in virtual screening: A critical review. J. Chem. Inf. Model 52, 867–881 (2012).
pubmed: 22435959
Dumitrascuta, M., Bermudez, M., Ballet, S., Wolber, G. & Spetea, M. Mechanistic understanding of peptide analogues, DALDA, [Dmt
Karimov, A. et al. Berberis alkaloids. XXIII. Structure of turcberine. Khim Prirodn Soedin 1, 77–81 (1993).
Adsersen, A. et al. Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from Corydalis cava Schweigg. & Kort. J. Ethnopharmacol. 113, 179–182 (2007).
pubmed: 17574358
Wang, X. et al. Preparative isolation of alkaloids from Dactylicapnos scandens using pH-zone-refining counter-current chromatography by changing the length of the separation column. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879, 3767–3770 (2011).
pubmed: 22056347
Han, J. W. et al. In vivo disease control efficacy of isoquinoline alkaloids isolated from Corydalis ternata against wheat leaf rust and pepper anthracnose. J. Microbiol. Biotechnol. 28, 262–266 (2018).
pubmed: 29141127
Wang, C. et al. Screening of antinociceptive components in Corydalis yanhusuo W.T. Wang by comprehensive two-dimensional liquid chromatography/tandem mass spectrometry. Anal. Bioanal. Chem. 396, 1731–1740 (2010).
pubmed: 20101504
Ruiz, A. et al. Flavonols, alkaloids, and antioxidant capacity of edible wild berberis species from Patagonia. J. Agric. Food Chem. 62, 12407–12417 (2014).
pubmed: 25495577
Wang, J. B. & Mantsch, J. R. l-Tetrahydropalamatine: A potential new medication for the treatment of cocaine addiction. Future Med. Chem. 4, 177–186 (2012).
pubmed: 22300097
China Pharmacopoeia Committee. Pharmacopoeia of People's Republic of China, China Chemical Industry Press, second ed. (2005).
Blumenthal, M., Busse, W.R., Goldbert, A., Gruenwald, J., Hall, T., Klein, S., Riggins, C.W. & Rister, R.S. The complete German E monographs-therapeutic guide to herbal medicines. American Botanical Council, Austin, TX, p. 310 (1998).
Sezik, E. et al. Traditional medicine in Turkey II. Folk medicine in Kastamonu. Int. J. Pharmacog. 30, 233–239 (1992).
Chang, H.-J. et al. Study on chemical constituents of Dicranostigma leptopodium (Maxim.) Fedde. Yaoxue Tongbao. 16, 52 (1981).
Qiu, Z. C. et al. Comparative study between Rhizoma Corydalis processing with vinegar and cleansing Rhizoma Corydalis in anti-inflammatory effect and analgesic effect. Prog. Mod. Biomed. 9, 4518–4521 (2009).
Li, R., Niu, Y.-B. & Dou, Z.-Y. Comparative study for pharmacological action of Corydalis Rhizoma before and after processing. Chin. Herb. Med. 7, 247–254 (2015).
Tang, W. & Eisenbrand, G. Chinese drugs of plant origin: Chemistry, pharmacology, and use in traditional and modern medicine 377–393 (Springer, Berlin, 1992).
Wang, J. et al. Preclinical pharmacokinetics, tissue distribution and excretion studies of a potential analgesics—corydaline using an ultra performance liquid chromatography-tandem mass spectrometry. J.. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 30, 942–943 (2013).
OMEGA 2.5.1.4: OpenEye Scientific Software, Santa Fe, NM. https://www.eyesopen.com/
Hawkins, P. C. D. et al. Conformer generation with OMEGA: Algorithm and validation using high quality structures from the protein databank and cambridge structural database. J. Chem. Inf. Model 50, 572–584 (2010).
pubmed: 20235588
pmcid: 2859685
Wolber, G. & Langer, T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model 45, 160–169 (2005).
pubmed: 15667141
Inte:Ligand GmbH (2015). LigandScout 3.1. Vienna: Inte:Ligand GmbH.
Madhavi Sastry, G. et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des. 27, 221–234 (2013).
pubmed: 23579614
de Bruyn Kops, C. et al. GLORY: generator of the Structures of likely cytochrome P450 metabolites based on predicted sites of metabolism. Front. Chem. 7, 402 (2019).
pubmed: 31249827
pmcid: 6582643
Sturm, S. et al. Analysis of central European Corydalis species by nonaqueous capillary electrophoresis—electrospray ion trap mass spectrometry. J. Chromatogr. A 1159, 41–50 (2007).
Bradford, M. M. A Rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254 (1976).
pubmed: 942051
Cheng, Y. & Prusoff, W. H. Relationship between the inhibition constant (k1) and the concentration of inhibitor which causes 50 per cent inhibition (i50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099–3108 (1973).
pubmed: 4202581